Efficacy and safety of endovascular treatment for femoropopliteal lesions of TASC II type C and D compared with TASC II type A and B in Korea. (August 2017)

• Record Type: Journal Article
• Authors: Joo, Hyung Joon; Jang, Duck Hyun; Yu, Cheol Woong; Choi, Young Jin; Park, Jinsik; Lee, Hyun Jong; Park, Jae Hyoung; Hong, Soon Jun; Lim, Do Sun
• Is Part Of: Vascular. Volume 25:Number 4(2017)
• Page Start: 351
• Page End: 358
• Publication Date: 2017-08
• Subjects: Endovascular procedures -- peripheral arterial disease -- treatment outcome; 616.13
• DOI: 10.1177/1708538116678539
• Languages: English
• ISSNs: 1708-5381

Abstract

Objective: To compare the long-term safety and clinical efficacy of endovascular treatment for TASC-II type C/D femoropopliteal lesion compared with TASC-II type A/B femoropopliteal lesion in Korea. Methods: A total of 179 limbs [TASC-II A/B femoropopliteal lesion (group I, n = 105 limbs) and TASC-II C/D (group II, n = 74 limbs)] were retrospectively analyzed from patients who underwent angioplasty with or without primary stent implantation between February 2008 and November 2012 at two medical centers in South Korea. The major adverse limb event was defined as a composite of target lesion revascularization, symptom relapse with abnormal ankle brachial index, and major amputation. Results: Immediate procedural success rates were not significantly different (96.2% vs. 95.7%, p = 0.450). Although major adverse limb event, mainly driven by symptom relapse with abnormal ankle brachial index, were significantly higher in group II ( p = 0.013), the incidence of major amputation was very low and similar in both groups. Conclusion: Even though there were higher incidences of overall procedural complication and major adverse limb event, the technical success rate of endovascular treatment for TASC-II C/D femoropopliteal lesion was comparable to endovascular treatment for TASC-II A/B FPL without an increase in major procedural complications or serious clinical events during follow-up.